Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Lördag 31 Januari | 07:11:50 Europe / Stockholm

Svenska | English

Nykode Therapeutics

Bifogade filer

Attachment 251124

Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider

2025-11-24 16:40:00

Oslo, Norway, November 24, 2025 - Primary insider Michael Engsig, Chief
Executive Officer of Nykode Therapeutics ASA, has today acquired 46,356 shares
in Nykode Therapeutics ASA at a price of NOK 2.16 per share. Following the
transaction, Michael Engsig holds 118,150 shares in Nykode Therapeutics ASA. 

Please see further details in the attached document.

Nykode Therapeutics

Bifogade filer

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden